EyeGate Pharmaceuticals reported a net loss of $2.38 million in the first 3 months of 2018 compared with $2.92 million in the same period of 2017, according to a press release.
Revenue for the quarter totaled $1.096 million compared with $0.185 million in 2017’s first quarter.
Research and development costs increased from $1.815 million in the first 3 months of 2017 to $2.521 million in this year’s first quarter, which was attributed to activity related to anterior uveitis treatment candidate EGP-437.
General and administrative expenses for the quarter decreased from $1.289 million
Uncategorized